BSH 2018: Access to new agents
Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.
Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.
Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.
Dr Martin Kaiser (London) discusses recent work from the UK on identifying robust markers and how clinical decisions can be made according to the biology of the disease…. read more.
Hepatitis A viruses (HAVs) circulating in an ongoing outbreak among men who have sex with men (MSM) in the Lombardy region of Italy are predominantly attributable to strains… read more.
As a community IBD professionals are well aware of the need to raise the bar in terms of delivering quality care that maintains tight disease control and anticipates… read more.
Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term… read more.
Perianal fistula is a debilitating complication in CD which affects up to 50% of patients in the course of their disease…
As usual, there was a lot of new data in at ASH 2017 in myeloma. Above Professor S Vincent Rajkumar (Mayo Clinic, Rochester, USA) gives a great overview… read more.
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar… read more.
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
Advertisment